Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Biomarkers in Lung Cancer.

Sears CR, Mazzone PJ.

Clin Chest Med. 2020 Mar;41(1):115-127. doi: 10.1016/j.ccm.2019.10.004. Epub 2020 Jan 2. Review.

PMID:
32008624
2.

Appraising the Integral Role of the Electronic Health Record and Tracking Software in the Implementation of Lung Cancer Screening: A Perspective From the National Lung Cancer Roundtable.

Fathi JT, White CS, Greenberg GM, Mazzone PJ, Smith RA, Thomson CC.

Chest. 2019 Dec 23. pii: S0012-3692(19)34453-8. doi: 10.1016/j.chest.2019.12.004. [Epub ahead of print] No abstract available.

PMID:
31877270
3.

The CHEST Editorial Team: Serving Our Contributors and Readers.

Mazzone PJ.

Chest. 2019 Jul;156(1):1-3. doi: 10.1016/j.chest.2019.05.010. No abstract available.

PMID:
31279360
4.

Development of a Risk Prediction Model to Estimate the Probability of Malignancy in Pulmonary Nodules Being Considered for Biopsy.

Reid M, Choi HK, Han X, Wang X, Mukhopadhyay S, Kou L, Ahmad U, Wang X, Mazzone PJ.

Chest. 2019 Aug;156(2):367-375. doi: 10.1016/j.chest.2019.01.038. Epub 2019 Mar 30.

PMID:
30940455
5.

Molecular biomarkers for the evaluation of lung nodules.

Mazzone PJ.

Lancet Respir Med. 2019 Apr;7(4):297-298. doi: 10.1016/S2213-2600(18)30528-9. Epub 2019 Feb 15. No abstract available.

PMID:
30777671
6.

Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges.

Seijo LM, Peled N, Ajona D, Boeri M, Field JK, Sozzi G, Pio R, Zulueta JJ, Spira A, Massion PP, Mazzone PJ, Montuenga LM.

J Thorac Oncol. 2019 Mar;14(3):343-357. doi: 10.1016/j.jtho.2018.11.023. Epub 2018 Dec 4. Review.

7.

Principled Lung Cancer Screening Follows Screening Principles.

Mazzone PJ, Jett J.

Chest. 2018 Dec;154(6):1265-1266. doi: 10.1016/j.chest.2018.08.1056. No abstract available.

PMID:
30526961
8.

Response.

Mazzone PJ, Silvestri GA, Patel S, Kanne JP, Kinsinger LS, Wiener RS, Soo Hoo GW, Detterbeck FC.

Chest. 2018 Oct;154(4):997-998. doi: 10.1016/j.chest.2018.07.024. No abstract available.

PMID:
30290947
9.

Models to Estimate the Probability of Malignancy in Patients with Pulmonary Nodules.

Choi HK, Ghobrial M, Mazzone PJ.

Ann Am Thorac Soc. 2018 Oct;15(10):1117-1126. doi: 10.1513/AnnalsATS.201803-173CME. Review.

PMID:
30272500
10.

Response.

Mazzone PJ, Silvestri GA, Patel S, Kanne JP, Kinsinger LS, Wiener RS, Soo Hoo GW, Detterbeck FC.

Chest. 2018 Sep;154(3):716-717. doi: 10.1016/j.chest.2018.06.025. No abstract available.

PMID:
30195352
11.

Incorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement.

Rivera MP, Tanner NT, Silvestri GA, Detterbeck FC, Tammem├Ągi MC, Young RP, Slatore CG, Caverly TJ, Boyd CM, Braithwaite D, Fathi JT, Gould MK, Iaccarino JM, Malkoski SP, Mazzone PJ, Tanoue LT, Schoenborn NL, Zulueta JJ, Wiener RS; American Thoracic Society Assembly on Thoracic Oncology.

Am J Respir Crit Care Med. 2018 Jul 15;198(2):e3-e13. doi: 10.1164/rccm.201805-0986ST.

PMID:
30004250
12.

Rebuttal From Dr Mazzone.

Mazzone PJ.

Chest. 2018 Jun;153(6):1306-1308. doi: 10.1016/j.chest.2018.03.016. No abstract available.

PMID:
29884253
13.
14.

RNAseq analysis of bronchial epithelial cells to identify COPD-associated genes and SNPs.

Yeo J, Morales DA, Chen T, Crawford EL, Zhang X, Blomquist TM, Levin AM, Massion PP, Arenberg DA, Midthun DE, Mazzone PJ, Nathan SD, Wainz RJ, Nana-Sinkam P, Willey PFS, Arend TJ, Padda K, Qiu S, Federov A, Hernandez DR, Hammersley JR, Yoon Y, Safi F, Khuder SA, Willey JC.

BMC Pulm Med. 2018 Mar 5;18(1):42. doi: 10.1186/s12890-018-0603-y.

15.

Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.

Silvestri GA, Tanner NT, Kearney P, Vachani A, Massion PP, Porter A, Springmeyer SC, Fang KC, Midthun D, Mazzone PJ; PANOPTIC Trial Team.

Chest. 2018 Sep;154(3):491-500. doi: 10.1016/j.chest.2018.02.012. Epub 2018 Mar 1.

16.

Exercise capacity and cancer-specific quality of life following curative intent treatment of stage I-IIIA lung cancer.

Ha D, Ries AL, Mazzone PJ, Lippman SM, Fuster MM.

Support Care Cancer. 2018 Jul;26(7):2459-2469. doi: 10.1007/s00520-018-4078-4. Epub 2018 Feb 10.

17.

Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.

Mazzone PJ, Silvestri GA, Patel S, Kanne JP, Kinsinger LS, Wiener RS, Soo Hoo G, Detterbeck FC.

Chest. 2018 Apr;153(4):954-985. doi: 10.1016/j.chest.2018.01.016. Epub 2018 Feb 17.

PMID:
29374513
18.

Evaluation of a Serum Lung Cancer Biomarker Panel.

Mazzone PJ, Wang XF, Han X, Choi H, Seeley M, Scherer R, Doseeva V.

Biomark Insights. 2018 Jan 15;13:1177271917751608. doi: 10.1177/1177271917751608. eCollection 2018.

19.

Electromagnetic Navigational Bronchoscopy versus CT-guided Percutaneous Sampling of Peripheral Indeterminate Pulmonary Nodules: A Cohort Study.

Bhatt KM, Tandon YK, Graham R, Lau CT, Lempel JK, Azok JT, Mazzone PJ, Schneider E, Obuchowski NA, Bolen MA.

Radiology. 2018 Mar;286(3):1052-1061. doi: 10.1148/radiol.2017170893. Epub 2017 Nov 20.

PMID:
29156147
20.

Stakeholder Research Priorities for Smoking Cessation Interventions within Lung Cancer Screening Programs. An Official American Thoracic Society Research Statement.

Kathuria H, Detterbeck FC, Fathi JT, Fennig K, Gould MK, Jolicoeur DG, Land SR, Massetti GM, Mazzone PJ, Silvestri GA, Slatore CG, Smith RA, Vachani A, Zeliadt SB, Wiener RS; ATS Assembly on Thoracic Oncology.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1202-1212. doi: 10.1164/rccm.201709-1858ST.

21.

Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement.

Mazzone PJ, Sears CR, Arenberg DA, Gaga M, Gould MK, Massion PP, Nair VS, Powell CA, Silvestri GA, Vachani A, Wiener RS; ATS Assembly on Thoracic Oncology.

Am J Respir Crit Care Med. 2017 Oct 1;196(7):e15-e29. doi: 10.1164/rccm.201708-1678ST.

22.

Frequency of Incidental Findings and Subsequent Evaluation in Low-Dose Computed Tomographic Scans for Lung Cancer Screening.

Morgan L, Choi H, Reid M, Khawaja A, Mazzone PJ.

Ann Am Thorac Soc. 2017 Sep;14(9):1450-1456. doi: 10.1513/AnnalsATS.201612-1023OC.

PMID:
28421812
23.

The combined rapid detection and species-level identification of yeasts in simulated blood culture using a colorimetric sensor array.

Shrestha NK, Lim SH, Wilson DA, SalasVargas AV, Churi YS, Rhodes PA, Mazzone PJ, Procop GW.

PLoS One. 2017 Mar 15;12(3):e0173130. doi: 10.1371/journal.pone.0173130. eCollection 2017.

24.

Impact of a Lung Cancer Screening Counseling and Shared Decision-Making Visit.

Mazzone PJ, Tenenbaum A, Seeley M, Petersen H, Lyon C, Han X, Wang XF.

Chest. 2017 Mar;151(3):572-578. doi: 10.1016/j.chest.2016.10.027. Epub 2016 Nov 1.

PMID:
27815154
25.

Obstacles to and Solutions for a Successful Lung Cancer Screening Program.

Mazzone PJ.

Semin Respir Crit Care Med. 2016 Oct;37(5):659-669. Epub 2016 Oct 12. Review.

PMID:
27732988
26.

The Utility of Exercise Testing in Patients with Lung Cancer.

Ha D, Mazzone PJ, Ries AL, Malhotra A, Fuster M.

J Thorac Oncol. 2016 Sep;11(9):1397-410. doi: 10.1016/j.jtho.2016.04.021. Epub 2016 May 5. Review.

27.

The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.

Detterbeck FC, Franklin WA, Nicholson AG, Girard N, Arenberg DA, Travis WD, Mazzone PJ, Marom EM, Donington JS, Tanoue LT, Rusch VW, Asamura H, Rami-Porta R; IASLC Staging and Prognostic Factors Committee; Advisory Boards; Multiple Pulmonary Sites Workgroup.

J Thorac Oncol. 2016 May;11(5):651-665. doi: 10.1016/j.jtho.2016.01.025. Epub 2016 Mar 2.

28.

The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.

Detterbeck FC, Bolejack V, Arenberg DA, Crowley J, Donington JS, Franklin WA, Girard N, Marom EM, Mazzone PJ, Nicholson AG, Rusch VW, Tanoue LT, Travis WD, Asamura H, Rami-Porta R; IASLC Staging and Prognostic Factors Committee; Advisory Boards; Multiple Pulmonary Sites Workgroup; Participating Institutions.

J Thorac Oncol. 2016 May;11(5):681-692. doi: 10.1016/j.jtho.2015.12.114. Epub 2016 Mar 3.

29.

The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification.

Detterbeck FC, Nicholson AG, Franklin WA, Marom EM, Travis WD, Girard N, Arenberg DA, Bolejack V, Donington JS, Mazzone PJ, Tanoue LT, Rusch VW, Crowley J, Asamura H, Rami-Porta R; IASLC Staging and Prognostic Factors Committee; Advisory Boards; Multiple Pulmonary Sites Workgroup; Participating Institutions.

J Thorac Oncol. 2016 May;11(5):639-650. doi: 10.1016/j.jtho.2016.01.024. Epub 2016 Mar 3.

30.

The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification.

Detterbeck FC, Marom EM, Arenberg DA, Franklin WA, Nicholson AG, Travis WD, Girard N, Mazzone PJ, Donington JS, Tanoue LT, Rusch VW, Asamura H, Rami-Porta R; IASLC Staging and Prognostic Factors Committee; Advisory Boards; Multiple Pulmonary Sites Workgroup.

J Thorac Oncol. 2016 May;11(5):666-680. doi: 10.1016/j.jtho.2015.12.113. Epub 2016 Mar 3.

31.

Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository.

Crawford EL, Levin A, Safi F, Lu M, Baugh A, Zhang X, Yeo J, Khuder SA, Boulos AM, Nana-Sinkam P, Massion PP, Arenberg DA, Midthun D, Mazzone PJ, Nathan SD, Wainz R, Silvestri G, Tita J, Willey JC.

BMC Pulm Med. 2016 Jan 22;16:16. doi: 10.1186/s12890-016-0178-4.

32.

Metabolite Profiles of the Serum of Patients with Non-Small Cell Carcinoma.

Mazzone PJ, Wang XF, Beukemann M, Zhang Q, Seeley M, Mohney R, Holt T, Pappan KL.

J Thorac Oncol. 2016 Jan;11(1):72-8. doi: 10.1016/j.jtho.2015.09.002.

33.

Accuracy of volatile urine biomarkers for the detection and characterization of lung cancer.

Mazzone PJ, Wang XF, Lim S, Choi H, Jett J, Vachani A, Zhang Q, Beukemann M, Seeley M, Martino R, Rhodes P.

BMC Cancer. 2015 Dec 23;15:1001. doi: 10.1186/s12885-015-1996-0.

34.

An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice.

Wiener RS, Gould MK, Arenberg DA, Au DH, Fennig K, Lamb CR, Mazzone PJ, Midthun DE, Napoli M, Ost DE, Powell CA, Rivera MP, Slatore CG, Tanner NT, Vachani A, Wisnivesky JP, Yoon SH; ATS/ACCP Committee on Low-Dose CT Lung Cancer Screening in Clinical Practice.

Am J Respir Crit Care Med. 2015 Oct 1;192(7):881-91. doi: 10.1164/rccm.201508-1671ST.

35.

Heart Rate Recovery as a Preoperative Test of Perioperative Complication Risk.

Ha D, Fuster M, Ries AL, Wagner PD, Mazzone PJ.

Ann Thorac Surg. 2015 Nov;100(5):1954-62. doi: 10.1016/j.athoracsur.2015.06.085. Epub 2015 Sep 26. Review.

PMID:
26410158
36.

Progress in the development of volatile exhaled breath signatures of lung cancer.

Mazzone PJ, Wang XF, Lim S, Jett J, Choi H, Zhang Q, Beukemann M, Seeley M, Martino R, Rhodes P.

Ann Am Thorac Soc. 2015 May;12(5):752-7. doi: 10.1513/AnnalsATS.201411-540OC.

37.

Cystic lung disease: systematic, stepwise diagnosis.

Ha D, Yadav R, Mazzone PJ.

Cleve Clin J Med. 2015 Feb;82(2):115-27. doi: 10.3949/ccjm.82a.14020. Review.

38.

Validation of a multiprotein plasma classifier to identify benign lung nodules.

Vachani A, Pass HI, Rom WN, Midthun DE, Edell ES, Laviolette M, Li XJ, Fong PY, Hunsucker SW, Hayward C, Mazzone PJ, Madtes DK, Miller YE, Walker MG, Shi J, Kearney P, Fang KC, Massion PP.

J Thorac Oncol. 2015 Apr;10(4):629-37. doi: 10.1097/JTO.0000000000000447.

39.

Association of impaired heart rate recovery with cardiopulmonary complications after lung cancer resection surgery.

Ha D, Choi H, Zell K, Raymond DP, Stephans K, Wang XF, Videtic G, McCarthy K, Minai OA, Mazzone PJ.

J Thorac Cardiovasc Surg. 2015 Apr;149(4):1168-73.e3. doi: 10.1016/j.jtcvs.2014.11.037. Epub 2014 Nov 21.

40.

Endobronchial ultrasonography-guided transbronchial needle aspiration, an effective modality for sampling targeted thoracic lesions in adult lung transplant recipients.

Sturgis CD, Brainard JA, Sethi S, Farver CF, Budev MM, Mazzone PJ, Abdul-Karim FW.

J Am Soc Cytopathol. 2015 Nov - Dec;4(6):321-326. doi: 10.1016/j.jasc.2015.04.003. Epub 2015 May 1.

PMID:
31051746
41.

Heart rate recovery and survival in patients undergoing stereotactic body radiotherapy for treatment of early-stage lung cancer.

Ha D, Stephans K, Choi H, Zell K, Wang XF, Minai OA, Raymond DP, Videtic G, Mazzone PJ.

J Radiosurg SBRT. 2015;3(3):193-201.

42.

Survival in patients with metachronous second primary lung cancer.

Ha D, Choi H, Chevalier C, Zell K, Wang XF, Mazzone PJ.

Ann Am Thorac Soc. 2015 Jan;12(1):79-84. doi: 10.1513/AnnalsATS.201406-261OC.

PMID:
25494009
43.

Serum free fatty acid biomarkers of lung cancer.

Liu J, Mazzone PJ, Cata JP, Kurz A, Bauer M, Mascha EJ, Sessler DI.

Chest. 2014 Sep;146(3):670-679. doi: 10.1378/chest.13-2568.

PMID:
24743744
44.

Quality indicators for the evaluation of patients with lung cancer.

Mazzone PJ, Vachani A, Chang A, Detterbeck F, Cooke D, Howington J, Dodi A, Arenberg D.

Chest. 2014 Sep;146(3):659-669. doi: 10.1378/chest.13-2900.

45.

Quality of life and healthcare use in a randomized controlled lung cancer screening study.

Mazzone PJ, Obuchowski N, Fu AZ, Phillips M, Meziane M.

Ann Am Thorac Soc. 2013 Aug;10(4):324-9. doi: 10.1513/AnnalsATS.201301-007OC.

46.

An attempt to reach the galaxy of the pulmonary nodules.

Mehta AC, Mazzone PJ.

Am J Respir Crit Care Med. 2013 Aug 1;188(3):264-5. doi: 10.1164/rccm.201305-0982ED. No abstract available.

PMID:
23905518
47.

Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, Wiener RS.

Chest. 2013 May;143(5 Suppl):e93S-e120S. doi: 10.1378/chest.12-2351. Review.

48.

Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB.

Chest. 2013 May;143(5 Suppl):e78S-e92S. doi: 10.1378/chest.12-2350. Review.

49.

Lung cancer screening with computer aided detection chest radiography: design and results of a randomized, controlled trial.

Mazzone PJ, Obuchowski N, Phillips M, Risius B, Bazerbashi B, Meziane M.

PLoS One. 2013;8(3):e59650. doi: 10.1371/journal.pone.0059650. Epub 2013 Mar 20.

50.

Beyond the usual suspects.

Mazzone PJ.

J Thorac Oncol. 2012 Oct;7(10):1477-8. doi: 10.1097/JTO.0b013e3182691425. No abstract available.

Supplemental Content

Loading ...
Support Center